NCT02287779View on ClinicalTrials.gov

Safety and Tolerability Study of SHP626 in Overweight and Obese Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

84

Participants

Timeline

Start Date

January 19, 2015

Primary Completion Date

June 19, 2015

Study Completion Date

June 19, 2015

Conditions
Non-Alcoholic Steatohepatitis
Interventions
DRUG

SHP626

DRUG

Placebo

Trial Locations (1)

37920

New Orleans Center for Clinical Research, Knoxville

Sponsors
All Listed Sponsors
lead

Mirum Pharmaceuticals, Inc.

INDUSTRY